104: Fundamentals of Embolization-Fundamentals of Embolization

Video Transcription

Video Summary

In a recent ASLD webinar, Dr. Charles Kim from Duke University discussed non-radioembolization therapies for liver cancer, particularly hepatocellular carcinoma (HCC). Dr. Kim detailed the use of embolization therapies, including bland and chemoembolization, as treatment options for patients who are not candidates for resection, ablation, or radioembolization. While these therapies might be less effective overall compared to newer treatments, they are gentler on liver function, making them suitable for patients with significant liver damage or in cases of ruptured HCCs. Dr. Kim highlighted that embolization therapies can be both therapeutic and palliative and are crucial for managing complex HCC cases, offering an alternative when other options are not viable. Despite advances in treatments such as radioembolization, these therapies remain important due to their ability to manage multifocal or large tumors with less impact on liver function.

Keywords

liver cancer

hepatocellular carcinoma

embolization therapies

chemoembolization

liver function

Dr. Charles Kim